logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2025
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
    • Managing Loss of Exclusivity Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • Cracking the Code 2.0
  • LINKS
  • CONTACT US
logo-top-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2025
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
    • Managing Loss of Exclusivity Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • Cracking the Code 2.0
  • LINKS
  • CONTACT US

Canada Attempts Biosimilar Balancing Act

March 2, 2017
-
Publications
-
Posted by MORSE Team - < 1 min read.

Pink Sheet Pharma Intelligence published the attached article by Francesca Bruce on February 17, 2017.  The article provides a helpful summary of the current pan-Canadian Pharmaceutical Alliance (pCPA) Biologics/Biosimilar Consultations.  We thank Ms. Bruce for seeking our perspective on this topic and Pink Sheet for granting permission to post this article.

 

A copy of the article can be downloaded here.

 

Source article on Pink Sheet

 

To receive timely industry updates and insights please be sure to sign up for Market Access Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
pCPA
← PREVIOUS POST
The pan-Canadian Cancer Drug Funding Sustainability Initiative
NEXT POST →
Terms of Reference for Scientific Advisory Panel on Opioid Use and Contraindications

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

CTC Event Vancouver

Carcking the code Vancouver

Pre-order 2026 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
Social
Connect & Follow:
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2026 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Canada Attempts Biosimilar Balancing Act
Learn More
Learn More